老龄化和临床前阿尔茨海默病中微妙认知衰退的客观标准:系统性审查
Kelsey R Thomas1,2, Emily C Edmonds3,4
1Department of Psychiatry, University of California, San Diego, La Jolla.
Neurology
|April 8, 2025
概括
本次审查确定了使用老年人客观测试来定义微妙认知衰退 (SCD) 的六种方法. 最常见的方法是客观定义的SCD和Pre-MCI,但需要更多的研究来比较它们的有效性.
科学领域:
- 神经学 神经学
- 老年学是指老年学的学科.
- 认知科学 认知科学
背景情况:
- 阿尔茨海默病 (AD) 诊断标准强调早期发现.
- 微妙的认知衰退 (SCD) 在认知不受损的个体中被认可.
- 对SCD的客观测量需要进行系统的审查.
研究的目的:
- 识别和描述用于对客观微妙认知衰退 (SCD) 的分类方法.
- 通过客观的神经心理测量来审查SCD的操作定义.
主要方法:
- 在PubMed/MEDLINE,科学网,PsycInfo数据库中进行系统的文献搜索 (截至2023年11月).
- 包括50岁以上没有MCI或痴呆症的参与者的同行评审研究,重点关注衰老或AD.
- 通过修改的纽卡斯尔-太华尺度评估研究质量,并提取了关于SCD分类方法的数据.
主要成果:
- 70个病例控制研究符合纳入标准.
- 确定了六个类别的SCD分类:单一测试截止值,复合分数截止值,多项测量截止值 (Obj-SCD),MCI前标准,纵向下降率和数据驱动的集群.
- 客观定义的SCD (Obj-SCD) 和Pre-MCI是最常用的方法.
结论:
- 有六种有希望的方法来对客观SCD进行分类.
- 最常见的方法是Obj-SCD和Pre-MCI.
- 需要进一步的研究来比较这些方法的预后效用,特别是在不同的人群中.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.0K
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
13.9K
相关概念视频
01:26Alzheimer's Disease: Overview
342
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
342
01:30Cognitive Development During Adulthood
32
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
32
01:22Alzheimer's Disease: Treatment
133
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
133
01:30Dementia
74
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
74
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
86
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
86